Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01546038 · ClinicalTrials.gov registry record · Phase 2

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase 2 study of Acute Myeloid Leukemia, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
255
Enrollment target
20
Study locations

NCT01546038 is a Phase 2 study of Acute Myeloid Leukemia that has completed, run by Pfizer. The registered enrollment target is 255 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (122% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01546038, a Phase 2 study of Acute Myeloid Leukemia, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
255 participants
Enrollment target
20
Study locations

Study Summary

This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG Decitabine
  • DRUG PF-04449913
  • DRUG Low dose ARA-C (LDAC)

Study Locations (20)

California

  • UC San Diego Moores Cancer Center - Investigational Drug Services - La Jolla
  • UC San Diego Medical Center - La Jolla - La Jolla
  • UC San Diego Moores Cancer Center - La Jolla
  • Keck Hospital of USC - Los Angeles
  • LAC & USC Medical Center - Los Angeles
  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services - Los Angeles
  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • Ronald Reagan UCLA Medical Center Drug Information Center - Los Angeles
  • Ronald Reagan UCLA Medical Center - Los Angeles
  • UCLA Drug lnformation/lnvestigational Drugs - Los Angeles
  • UCLA Hematology/Oncology Clinic - Los Angeles
  • UC San Diego Medical Center - Hillcrest - San Diego

Alabama

  • University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham - Birmingham

Colorado

  • University of Colorado Denver - Aurora
  • University of Colorado Hospital - Aurora

Georgia

  • Emory University Hospital - Atlanta
  • Investigational Drug Service, Emory University Clinic - Atlanta

Florida

  • H.Lee Moffitt Cancer Center and Research Institute - Tampa

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2012-06-27
Est. Completion 2019-03-04
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01546038

The ClinicalTrials.gov registry entry for NCT01546038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (122% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Decitabine is the first listed.

NCT01546038 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT01546038 about?

NCT01546038 is a clinical study titled "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome". This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.

What is the current status of trial NCT01546038?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2012-06-27. Estimated completion is 2019-03-04.

What conditions does trial NCT01546038 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT01546038?

The interventions under investigation include: Decitabine (DRUG), PF-04449913 (DRUG), Low dose ARA-C (LDAC) (DRUG).

Who is sponsoring clinical trial NCT01546038?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01546038 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.